Detalhe da pesquisa
1.
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.
Biol Blood Marrow Transplant
; 26(6): 1210-1217, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32088366
2.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Blood
; 132(25): 2639-2642, 2018 12 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30266774
3.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Lancet
; 389(10068): 519-527, 2017 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28017406
4.
Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis.
Cancer
; 123(8): 1416-1423, 2017 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27893933
5.
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
Biol Blood Marrow Transplant
; 22(5): 869-78, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26827660
6.
Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.
Biol Blood Marrow Transplant
; 22(12): 2256-2263, 2016 12.
Artigo
Inglês
| MEDLINE | ID: mdl-27565521
7.
Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers.
Biol Blood Marrow Transplant
; 22(3): 520-7, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26597080
8.
Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).
Cancer
; 122(1): 91-8, 2016 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26439325
9.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 385(9980): 1853-62, 2015 May 09.
Artigo
Inglês
| MEDLINE | ID: mdl-25796459
10.
Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
Biol Blood Marrow Transplant
; 21(2): 335-41, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25445028
11.
Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers.
Biol Blood Marrow Transplant
; 21(10): 1830-8, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26116089
12.
Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.
Biol Blood Marrow Transplant
; 20(10): 1530-6, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24910380
13.
Older patients with myeloma derive similar benefit from autologous transplantation.
Biol Blood Marrow Transplant
; 20(11): 1796-803, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25046833
14.
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
J Clin Apher
; 29(6): 293-8, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24700728
15.
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Biol Blood Marrow Transplant
; 19(1): 56-61, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22892551
16.
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Biol Blood Marrow Transplant
; 19(6): 925-33, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23529012
17.
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Support Care Cancer
; 21(9): 2437-42, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23591714
18.
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.
Biol Blood Marrow Transplant
; 18(9): 1455-61, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22453252
19.
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Blood
; 116(26): 5838-41, 2010 Dec 23.
Artigo
Inglês
| MEDLINE | ID: mdl-20876454
20.
Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.
Support Care Cancer
; 20(10): 2363-9, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22193771